New drug shows sustained benefit at 2 years in rare blood cancer
the ONA take:
Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia, a rare blood cancer.
In addition, 95% of patients receiving the newly approved drug are experiencing progression-free survival 2 years after initiating treatment. When progression did occur, it began at a median of 9.6 months after the start of treatment.
Waldenstrom macroglobulinemia is caused by an abnormality in the B lymphocytes in bone marrow that causes the overproduction of IgM, an immunoglobulin protein that thickens the blood.
It is driven by the MYD88 and CXCR4 genetic mutations. MYD88 mutation triggers abnormal activity of Bruton’s tyrosine kinase. Ibrutinib targets a pathway involving Bruton’s tyrosine kinase protein.
The trial included 63 patients who had received at least one prior treatment. The drug is administered as an oral drug taken daily.
Treatment continued until the disease worsened or unacceptable toxic effects occurred. Response rate in the study refers to the degree of reduction in IgM in the blood.
Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|